

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT EXAMINING OPERATION**

Applicant(s): David FAIRLIE et al.

Serial No: 10/596,074

Group Art Unit: 1625

Filed: January 25, 2007

Examiner: Nizal S. Chandrakumar

Att. Docket No.: P1119/20002

Confirmation No.: 1505

For: ANTI-CANCER AGENTS


PROVISIONAL ELECTION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the restriction requirement set forth in the July 22, 2008 Office Action, Applicants hereby provisionally elect without traverse Group I, claims 84-114 and 138, drawn to compounds of Formula I.

In response to the species election requirement, Applicants hereby provisionally elect without traverse the species of Formula IIIa and the single disclosed compound of Formula IIIa having the following formula:



Elected claims 88-102 read on compounds of Formula IIIa. Elected claims 84-87 and 138 are generic to compounds of Formula IIIa.

It is respectfully submitted that the application is in good form for initial examination on the merits. Accordingly, prompt and favorable examination on the merits is respectfully requested.

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN,
COHEN & POKOTILOW, LTD.

By _____

David M. Tener
Registration No. 37,054
Customer No. 03000
(215) 567-2010
Attorneys for Applicant(s)

September 19, 2008

Please charge or credit our Account
No. 03-0075 as necessary to effect
entry and/or ensure consideration of
this submission.